You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on minimal residual disease testing.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
Under the non-exclusive deal, Natera will use matched tumor and normal exome sequencing data from Personalis to validate the design of its Signatera ctDNA assays.
Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.
Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.